Anika Therapeutics (ANIK) Leases (2016 - 2025)
Historic Leases for Anika Therapeutics (ANIK) over the last 13 years, with Q3 2025 value amounting to $24.2 million.
- Anika Therapeutics' Leases fell 1096.0% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 1096.0%. This contributed to the annual value of $25.7 million for FY2024, which is 678.3% down from last year.
- Latest data reveals that Anika Therapeutics reported Leases of $24.2 million as of Q3 2025, which was down 1096.0% from $24.7 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Leases ranged from a high of $31.6 million in Q2 2022 and a low of $20.5 million during Q1 2022
- Over the past 5 years, Anika Therapeutics' median Leases value was $27.2 million (recorded in 2024), while the average stood at $26.3 million.
- As far as peak fluctuations go, Anika Therapeutics' Leases soared by 4707.32% in 2023, and later crashed by 1096.0% in 2025.
- Quarter analysis of 5 years shows Anika Therapeutics' Leases stood at $21.0 million in 2021, then skyrocketed by 46.47% to $30.7 million in 2022, then fell by 10.24% to $27.6 million in 2023, then decreased by 6.78% to $25.7 million in 2024, then fell by 5.68% to $24.2 million in 2025.
- Its last three reported values are $24.2 million in Q3 2025, $24.7 million for Q2 2025, and $25.2 million during Q1 2025.